A Tiny Cure for Cancer?

From Bev Jedynak

Hi – interesting article in the July/August issue on Aura Biosciences. Just had to drop you a note though – I am the pr rep for pSivida Corp., a Boston-based NASDAQ company (PSDV) that actually has developed a nano-structured form of silicon, doped with P32 as a brachytherapy for pancreatic cancer. The product, called BrachySil, is injected into the pancreatic cancer tumor of a patient and because the P32 is beta radiation, it zaps the tumor. Some data from trials in humans during a Phase IIa clinical trial was presented last January at the ASCO-GI conference (I can send the poster, if there is interest). And, Phase IIb – a dosing study, has just commenced. This particular treatment is already in humans with some pretty good results — even though those results are early, they are very encouraging. I doubt that you will be returning to the subject, but just wanted to give you feedback on it — that something like this is already being done in human beings.

Thanks

From Srihari,Seattle,Wa

Great work!!!

This come for a person who's father passed away in 2004 due to Multiple myeloma. So any cure for cancer treatment is always close to my heart.

From Tom Holzel

To the Editor–

I really got a hair up my butt about last month's issue which I complained sounded like it was written by a coven of stay-at-home moms pretending to be businessmen. (Maybe I'm still bummed out by your kow -towing to Paul Moller. After the editors accepted my letter pointing out that he had reneged on 40-years (!) of promises to prospects an investors, they began a series of hedging their bets. First this part was cut out–"O.K.?" then another call to cut more. What finally saw the light of day was a pale shadow of what I had written.) Paul had simply conned another editor.

Of course he's gone belly-up now and had to deal with an SEC fraud issue to boot. Maybe you could do a follow-up as a useful case study.

In any case, this month's article "A tiny cure for Cancer" was a complete reversal of that noxious tendency–paraphrasing company press releases. It was logical, factual and quickly got to the point. Most importantly, it provided exculpatory evidence–a feature so sadly missing from most business articles.

Good work, and I apologize to who ever's ox I gored.

Tom Holzel, Principal
http://www.velocityassociates.net